In vitro anti-HIV potency of stampidine alone and in combination with standard anti-HIV drugs

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 4, 2005, Pages 223-231

  Uckun, Fatih M ^a,b,c   Qazi, Sanjive ^a   Venkatachalam, T K ^a,c  

^a PARKER HUGHES INSTITUTE   (United States)

^b Drug Discovery Program   (United States)

^c Paradigm Pharmaceuticals   (United States)

Author keywords

Anti retroviral drugs; CAS 217178 62 6; Stampidine, anti HIV activity in vitro, drug combination, HIV isolates

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAMPIDINE; STAVUDINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SENSITIVITY; ENZYME IMMUNOASSAY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; REGRESSION ANALYSIS; VIRUS REPLICATION;

EID: 17644412826     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296849     Document Type: Article

References (45)

1. Sepkowitz, K. A., AIDS - the first 20 years. N. Engl. J. Med. 344, 1764 (2001)
2. Gottlieb, M. S., AIDS - past and future. N. Engl. J. Med. 344, 1788 (2001)
3. Freedberg, K. A., Losina, E., Weinstein, M. C., et al., The cost effectiveness of combination antiretroviral therapy for HIV disease. N. Engl. J. Med. 344, 824 (2001)
4. Richman, D. D., HIV chemotherapy. Nature 410, 995 (2001)
5. Shafer, R. W., Vuitton, D. A., Highly active antiretroviral therapy (HAART) for the treatment of infection with human immunodeficiency virus type 1. Biomed Pharmacother. 53, 73 (1999)
6. Starr, S. E., Fletcher, C. V, Spector, S. A., et al., Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team. N. Engl. J. Med. 341, 1874 (1999)
7. Rey, D., Schmitt, M. P., Partisani, M., et al., Efavirenz as a substitute for protease inhibitors in HIV-1-infected patients with undetectable plasma viral load on HAART: a median follow-up of 64 weeks. J. Acquir. Immune Defic. Syndr. 27, 459 (2001)
8. Miller, V., Ait-Khaled, M., Stone, C. et al., HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy. AIDS 14, 163 (2000)
9. Ross, L., Scarsella, A., Raffanti, S. et al., Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in hiv type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens. AIDS Res. Hum. Retroviruses 17, 1107 (2001)
10. Coakley, E. P., Gillis, J. M., Hammer, S. M., Phenotypic and genotypic resistance patterns of HIV-1 isolates derived from individuals treated with didanosine and stavudine. AIDS 14, F9 (2000)
11. Johnson, V. A., Nucleoside reverse transcriptase inhibitors and resistance of human immunodeficiency virus type 1. J. Infect. Dis. 171, S140 (1995)
12. Lin, P. F., Gonzalez, C. J., Griffith, B. et al., Stavudine resistance: an update on susceptibility following prolonged therapy. Antivir. Ther. 4, 21 (1999)
13. Suzuki, K., Kaufmann, G. R., Mukaide, M. et al., Novel deletion of HIV type 1 reverse transcriptase residue 69 conferring selective high-level resistance to nevirapine. AIDS Res. Hum. Retroviruses 17, 1293 (2001)
14. Picard, V., Angelini, E., Maillard, A. et al., Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine. J. Infect. Dis. 184, 781 (2001)
15. Miller, M. D., Margot, N. A., Lamy, P. D. et al., Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: genotypic and phenotypic analyses of study GS-96-408. J. Acquir. Immune Defic. Syndr. 27, 450 (2001)
16. Shulman, N. S., Machekano, R. A., Shafer, R. W. et al., The AIDS Clinical Trials Group 302 Study Team. Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy. J. Acquir. Immune Defic. Syndr. 27, 377 (2001)
17. Izopet, J., Bicart-See, A., Pasquier, C. et al., Mutations conferring resistance to zidovudine diminish the antiviral effect of stavudine plus didanosine. J. Med. Virol. 59, 507 (1999)
18. Venturi, G., Romano, L., Catucci, M, et al., Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse-transcriptase inhibitors. Eur. J. Clin. Microbiol. Infect. Dis. 18, 274 (1999)
19. Kuritzkes, D. R., Sevin, A., Young, B. et al., Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team, J. Infect. Dis. 181, 491 (2000)
20. O'Brien, W. A., Resistance against reverse transcriptase inhibitors. Clin. Infect. Dis. 30, S185 (2000)
21. Pillay, D., Taylor, S., Richman, D. D., Incidence and impact of resistance against approved antiretroviral drugs. Rev. Med. Virol. 10, 231 (2000)
22. Rousseau, M. N., Vergne, L., Montes, B. et al., Patterns of resistance mutations to antiretroviral drugs in extensively treated HIV-1-infected patients with failure of highly active antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 26, 36 (2001)
23. Briones, C., Soriano, V., Gonzalez-Lahoz, J., Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. Aids 14, 1659 (2000)
24. Gutierrez, F., Molto, J., Escolano, C. et al., Genotypic resistance to antiretroviral drugs in patients with therapeutic failure to highly active antiretroviral therapy. Med. Clin. (Barc). 115, 401 (2000)
25. Palmer, S., Shafer, R. W., Merigan, T. C., Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS 13, 661 (1999)
26. Duwe, S., Brunn, M., Altmann, D. et al., Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J. Acquir. Immune Defic. Syndr. 26, 266 (2001)
27. Salomon, H., Wainberg, M. A., Brenner, B. et al., Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 14, F17 (2000)
28. Aryl Phosphate Derivatives of d4T Having Anti-HIV Activity, US Patent Number 6,030,957, issue date 2/29/00, Uckun, F. M., Vig, R., Parker Hughes Institute, St. Paul, MN (USA)
29. Erice, A., Balfour, H. H., Jr., Myers, D. E. et al., Anti-human immunodeficiency virus type 1 activity of an anti-CD4 immunoconjugate containing pokeweed antiviral protein. Antimicrob. Agents Chemother. 37, 835 (1993)
30. Richman, D. D., Johnson, V. A., Mayers, D. L. et al., Current Protocols in Immunology, Suppl 8, Unit 12.1-12.5. John Wiley & Sons, Brooklyn, NY (1993)
31. Uckun, F. M., Chelstrom, L. M., Tuel-Ahlgren, L. et al., TXU (anti-CD7)-pokeweed antiviral protein as a potent inhibitor of human immunodeficiency virus. Antimicrob. Agents Chemother. 42, 383 (1998)
32. Greco, W. R., Bravo, G., Parsons, J. C., The search for synergy: a critical review from a response surface perspective. Pharmacol. Rev. 47, 331 (1995)
33. Dressler, V., Muller, G., Suhnel, J., CombiTool-a new computer program for analyzing combination experiments with biologically active agents. Comput, Biomed. Res. 32, 145 (1999)
34. Snyder, S., D'Argenio, D. Z., Weislow, O. et al., The triple combination indinavir-zidovudine-lamivudine is highly synergistic. Antimicrob, Agents Chemother. 44, 1051 (2000)
35. Rana, K. Z., Dudley, M. N., Clinical pharmacokinetics of stavudine. Clin. Pharmacokinet. 33, 276 (1997)
36. Venkatachalam, T. K., Tai, H.-L., Vig, R. et al., Enhancing Effects of a Mono-Bromo Substitution at the Para Position of the Phenyl Moiety on the Metabolism and Anti-HIV Activity of D4T-Phenyl Methoxyalaninyl Phosphate Derivatives. Bioorg. Med. Chem. Lett. 8, 3121 (1998)
37. Vig, R., Venkatachalam, T. K., Uckun, F. M., D4T-5'-[p-bromophenyl methoxyalaninyl phosphate] as a potent and non- toxic anti-human immunodeficiency virus agent. Antivir. Chem. Chemother. 9, 445 (1998)
38. Uckun, F, M., Pendergrass, S., Venkatachalam, T. K. et al., Stampidine is a potent inhibitor of Zidovudine- and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical human immunodeficiency virus type 1 isolates with thymidine analog mutations. Antimicrob. Agents Chemother, 46, 3613 (2002)
39. Uckun, F. M., Pendergrass, S., Qazi, S. et al., In vitro activity of Stampidine against primary clinical human immunodeficiency virus isolates, Arzneim.-Forsch./Drug Res, 54, 69 (2004)
40. Chen, C., Venkatachalam, T. K., Zhu, Z. et al., In vivo pharmacokinetics and metabolism of Stampidine, a novel aryl phosphate derivative of d4T with potent anti-HIV activity. Drug Metab. Dispos. 29, 1035 (2001)
41. Uckun, F. M., Qazi, S., Pendergrass, S. et al., In vivo toxicity, pharmacokinetics, and anti-human immunodeficiency virus activity of stavudine-5′-(p-bromophenyl methoxyalaninyl phosphate) (Stampidine) in mice. Antimicrob, Agents Chemother, 46, 3428 (2002)
42. Uckun, F. M., Chen, C. L., Samuel, P. et al., In vivo antiretroviral activity of Stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob. Agents Chemother. 47, 1233 (2003)
43. D'Cruz, O. J., Uckun, F. M., Stampidine is a potential nonspermicidal broad-spectrum anti-human immunodeficiency virus microbicide. Fertil. Steril. 81 (Suppl. 1), 831 (2004)
44. D'Cruz, O. J., Samuel, P., Waurzyniak, B. et al., Development and evaluation of a thermoreversible ovule formulation of stampidine, a novel nonspermicidal broad-spectrum antihuman immunodeficiency virus microbicide. Biol. Reprod. 69, 1843 (2003)
45. Uckun, F. M., Chen, C. L., Lisowski, E. et al., Toxicity and pharmacokinetics of Stampidine in mice and rats. Arzneim,-Forsch./Drug Res. 53, 357 (2003)